SMYD3 and breast cancer: Additionally, the splenomegaly phenotype was reversed (Supplementary Fig. 8d, e), without obvious cytotoxicity in the spleen and liver (Supplementary Fig. 8f), demonstrating that Tra has a significant inhibitory effect in mammary tumors with elevated Smyd3-Shcbp1 signaling.